In the study of endometrial cancer (EC), we found that Brusatol sensitizes the cancer to progestins by inhibiting the NRF2-TET1-AKR1C1 pathway, which reduces AKR1C1 expression and decreases progesterone metabolism [110]. Here, AKR1C1 is linked to endometrial cancer.